SecBot SecBot
8-K ·Filed Apr 30, 2026

AXSM

Axsome Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001193125-26-197857
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This is a transformative label expansion for AUVELITY into a large, underserved market with no FDA-approved competition for Alzheimer's agitation. Watch for the company's commercial launch execution and prescription trends over the next 2-4 quarters. The conference call on May 1 may provide revenue guidance or launch expectations.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$206.53
T+0 close · Apr 30, 2026 · via day close
Latest settled
+13.40%
T+60 · $234.20
Vs SPY
+10.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $206.53entry
  2. T+1 · 7mo ago +8.31%α +8.65% · $223.70
  3. T+5 · 6mo ago +6.63%α +4.28% · $220.22
  4. T+20 · 6mo ago +11.48%α +6.20% · $230.25
  5. T+60 · 4mo ago +13.40%α +10.33% · $234.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment for a condition affecting up to 76% of Alzheimer's patients. This is a major label expansion for an already-approved drug (MDD), supported by Breakthrough Therapy designation and Priority Review, with a patent estate extending to at least 2043.

Key Facts

  • FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026.
  • AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors for this indication.
  • The sNDA was granted Breakthrough Therapy designation and evaluated under Priority Review.
  • Approval supported by Phase 3 ADVANCE-1 and ACCORD-2 trials showing statistically significant improvement on primary and key secondary endpoints.
  • AUVELITY is already FDA-approved for major depressive disorder (approved 2022) and has been administered to over 300,000 patients.
  • Patent estate extends to at least 2043.
  • Alzheimer's disease affects more than 7 million Americans; agitation reported in up to 76% of patients.

Financial Impact

No specific financial figures provided in the filing. The approval opens a large addressable market (up to ~5.3M Alzheimer's patients with agitation) for an existing commercial product.

revenue

Risk Factors

  • Commercial adoption may be slower than expected due to the elderly patient population and caregiver-driven prescribing dynamics.
  • Payer coverage and reimbursement for the new indication are not yet established.
  • AUVELITY carries a boxed warning for suicidal thoughts and behaviors, which may limit use in some patients.
  • Competition from off-label antipsychotics and other emerging therapies could limit market share.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-197857
Document: axsm-20260430.htm0001193125-26-197857
Document: 0001193125-26-197857-index-headers.html0001193125-26-197857
Document: 0001193125-26-197857-index.html0001193125-26-197857
Document: 0001193125-26-197857.txt0001193125-26-197857

Track record

26 reports on AXSM

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026